Shoreline Partners

Shoreline Biosciences is a clinical-stage biotechnology company focused on developing next-generation allogeneic, off-the-shelf cell therapies for cancer and other serious diseases. The company leverages its proprietary induced pluripotent stem cell (iPSC) platform to create standardized, scalable Natural Killer (NK) cell and macrophage therapeutics. By utilizing advanced genetic engineering and manufacturing techniques, Shoreline aims to overcome the limitations of current autologous cell therapies, such as high costs and complex logistics. Their pipeline includes candidates targeting various hematologic malignancies and solid tumors, supported by high-profile partnerships with major pharmaceutical companies.